<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013037</url>
  </required_header>
  <id_info>
    <org_study_id>CSR 205237</org_study_id>
    <secondary_id>Pro00028970</secondary_id>
    <nct_id>NCT02013037</nct_id>
  </id_info>
  <brief_title>The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation</brief_title>
  <acronym>DUET</acronym>
  <official_title>The De-novo Use of Eculizumab Alongside Conventional Therapy in Presensitized Patients Receiving Cardiac Transplantation: An Open-Label, Investigator-Initiated Pilot Trial: [The DUET Cardiac Trial]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      All individuals who receive a heart transplant are at risk for developing antibody-mediated&#xD;
      rejection (AMR). An antibody is a protein produced by the body's immune system when it&#xD;
      detects a foreign substance, called an antigen. The mechanism of an antibody is to attack an&#xD;
      antigen. In antibody mediated rejection, antibodies will attack the transplanted heart,&#xD;
      causing injury to the heart. The purpose of this investigation is to determine if a study&#xD;
      drug, called eculizumab (Soliris), is safe to use in heart transplant recipients, and&#xD;
      determine if it reduces risk of antibody-mediated rejection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The growing proportion of sensitized cardiac recipients presents an additional challenge to&#xD;
      the transplant practitioner attempting to minimize the occurrence of antibody mediated&#xD;
      rejection (AMR). Patients pre-exposed or &quot;sensitized&quot; to antigen exposing events (i.e.: blood&#xD;
      transfusions, multiple pregnancies, prior organ transplantations, ventricular support&#xD;
      devices) are more likely to both possess preformed and develop de-novo antibodies. Sensitized&#xD;
      patients with panel reactive antibodies &gt; 25% are at risk for increased risk of rejection,&#xD;
      development of cardiac allograft vasculopathy and increased mortality after heart&#xD;
      transplantation.&#xD;
&#xD;
      A central component of antibody-mediated cell injury is complement activation. The inhibition&#xD;
      of terminal complement activation may be the missing link to decreasing possibly both&#xD;
      complement-mediated AMR and cellular rejection (CR) by inhibiting both the inflammatory&#xD;
      effects of both circulating antibodies and cytokine induced cell death.&#xD;
&#xD;
      Eculizumab is a monoclonal antibody that specifically binds to complement protein C5 with&#xD;
      high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation&#xD;
      of the terminal complement complex C5b-9. By this mechanism, eculizumab (Soliris®) inhibits&#xD;
      terminal complement mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria&#xD;
      patients.&#xD;
&#xD;
      This study is a non-randomized, open-label, investigator-initiated safety and efficacy trial&#xD;
      investigating the de-novo use of eculizumab alongside conventional therapy to prevent&#xD;
      antibody mediated rejection. The duration of the study will include an open enrollment period&#xD;
      and at least 12 months of follow-up (post-transplant). We will consent up to 45 eligible&#xD;
      patients, highly &quot;sensitized&quot;, with a panel reactive antibody score greater than 70%, who are&#xD;
      not previously or currently enrolled in another ongoing trial. Of these 45 participants, up&#xD;
      to 20 of these patients will be treated with eculizumab (Solaris), the study drug. The use of&#xD;
      eculizumab will be un-blinded to all study and research practitioner participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction</measure>
    <time_frame>up to 26 weeks post heart transplant</time_frame>
    <description>The efficacy of Eculizumab will be assessed by a composite endpoint of:&#xD;
the incidence of pathologic AMR with a Grade ≥ 2&#xD;
the incidence of left ventricular dysfunction, as defined by a left ventricular ejection fraction (LVEF) ≤ 40% or a decrease of &gt;15% from baseline prior to the initiation of Eculizumab treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Survival at 12 Months Post Heart Transplantation</measure>
    <time_frame>1 year post heart transplant</time_frame>
    <description>The study will assess overall survival at 12 months following heart transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hemodynamic Compromise at 6 Months Post Transplant</measure>
    <time_frame>6 months post heart transplant</time_frame>
    <description>The incidence of patient hemodynamic compromise will be assessed at 6 months post transplant, as defined by any one of the following:&#xD;
a 20% decrease in LVEF from baseline&#xD;
a LVEF &lt; 40%&#xD;
a 25% decrease in cardiac index from baseline&#xD;
a cardiac index &lt; 2.0&#xD;
the need for inotropic support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hemodynamic Compromise at 1 Year Post Transplant</measure>
    <time_frame>1 year post heart transplant</time_frame>
    <description>The incidence of patient hemodynamic compromise will be assessed at one year post transplant, as defined by any one of the following:&#xD;
a 20% decrease in LVEF from baseline&#xD;
a LVEF &lt; 40%&#xD;
a 25% decrease in cardiac index from baseline&#xD;
a cardiac index &lt; 2.0&#xD;
the need for inotropic support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Antibody Mediated Rejection (AMR)</measure>
    <time_frame>up to 1 year post heart transplant</time_frame>
    <description>The study assessed the number of patients who develop AMR as well as the total number of episodes of AMR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With of Acute Cellular Rejection (ACR)</measure>
    <time_frame>up to 1 year post heart transplant</time_frame>
    <description>The study assessed the number of participants with of Acute Cellular Rejection (ACR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Cardiac Allograft Vasculopathy (CAV) by Intravascular Ultrasound (IVUS)</measure>
    <time_frame>up to 1 year post heart transplant</time_frame>
    <description>Development of cardiac allograft vasculopathy at 1 year determined by intravascular ultrasound defined as change in site-matched maximal intimal thickness ≥ 0.5mm from baseline to 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Evolution of DSA: Donor Specific Antibody Post Transplantation</measure>
    <time_frame>Up to 1 year post transplant</time_frame>
    <description>Number of Participants who develop de novo donor specific antibody (DSA) in the first year following transplantation was determined.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Antibody-mediated Rejection</condition>
  <condition>Hyperacute Rejection of Cardiac Transplant</condition>
  <condition>Left Ventricular Dysfunction</condition>
  <condition>Cardiac Allograft Vasculopathy</condition>
  <condition>Heart Graft Dysfunction</condition>
  <arm_group>
    <arm_group_label>Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of Eculizumab to heart transplant recipients at Cedars Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, for the prevention of antibody-mediated rejection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <description>At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.&#xD;
On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.&#xD;
On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.&#xD;
On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.&#xD;
On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit.</description>
    <arm_group_label>Eculizumab</arm_group_label>
    <other_name>Soliris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is ≥ 18 years of age.&#xD;
&#xD;
          -  Patient has a panel reactive antibody (PRA) ≥ 70% at any time prior to screening.&#xD;
&#xD;
          -  Patient is considered compliant and intends to be available for a minimum follow-up&#xD;
             study period of 1 year.&#xD;
&#xD;
          -  Patient must be vaccinated against Neisseria meningitides at least 2 weeks prior to&#xD;
             receiving treatment therapy or receive appropriate antibiotic prophylaxis for the&#xD;
             duration of eculizumab treatment if timely vaccination could not be achieved prior to&#xD;
             transplantation.&#xD;
&#xD;
          -  Voluntary written informed consent must be obtained before performance of any&#xD;
             study-related procedure not considered routine medical care, with the understanding&#xD;
             that consent may be withdrawn by the subject at any time without prejudice to future&#xD;
             medical care.&#xD;
&#xD;
          -  Female subject is either post-menopausal or surgically sterilized or willing to use&#xD;
             two acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine&#xD;
             device, diaphragm with spermicide, condom with spermicide, or abstinence) for the&#xD;
             duration of the study and for up to 2 months after the last dose of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Donor or recipient age is &lt; 18 years or &gt; 75 years.&#xD;
&#xD;
          -  Cold ischemia time is &gt; 6 hours.&#xD;
&#xD;
          -  Current clinical, radiographic, or laboratory evidence of active or latent&#xD;
             tuberculosis (TB), as determined by local standard of care.&#xD;
&#xD;
          -  History of active TB within the last 2 years, even if treated.&#xD;
&#xD;
          -  History of active TB greater than 2 years ago, unless there is documentation of&#xD;
             adequate treatment according to locally accepted clinical practice.&#xD;
&#xD;
        (Note: Patients at risk of TB reactivation preclude administration of conventional&#xD;
        immunosuppression, as determined by the study investigator and based upon appropriate&#xD;
        evaluation).&#xD;
&#xD;
          -  Receipt of desensitization treatment with rituximab less than 2 weeks prior to therapy&#xD;
             and cluster of differentiation antigen 20 (CD20) count &gt;2%.&#xD;
&#xD;
          -  Receipt of a live vaccine within 4 weeks prior to study entry.&#xD;
&#xD;
          -  Patients with current or recent severe systemic infections within the 2 weeks prior to&#xD;
             transplantation.&#xD;
&#xD;
          -  Prior history of splenectomy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jignesh Patel, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars Sinai Medical Center and Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center, Heart Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kfoury AG, Hammond ME, Snow GL, Drakos SG, Stehlik J, Fisher PW, Reid BB, Everitt MD, Bader FM, Renlund DG. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J Heart Lung Transplant. 2009 Aug;28(8):781-4. doi: 10.1016/j.healun.2009.04.035.</citation>
    <PMID>19632573</PMID>
  </reference>
  <reference>
    <citation>Uber WE, Self SE, Van Bakel AB, Pereira NL. Acute antibody-mediated rejection following heart transplantation. Am J Transplant. 2007 Sep;7(9):2064-74. Epub 2007 Jul 5. Review.</citation>
    <PMID>17614978</PMID>
  </reference>
  <reference>
    <citation>Wu GW, Kobashigawa JA, Fishbein MC, Patel JK, Kittleson MM, Reed EF, Kiyosaki KK, Ardehali A. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant. 2009 May;28(5):417-22. doi: 10.1016/j.healun.2009.01.015. Epub 2009 Mar 14.</citation>
    <PMID>19416767</PMID>
  </reference>
  <reference>
    <citation>Michaels PJ, Espejo ML, Kobashigawa J, Alejos JC, Burch C, Takemoto S, Reed EF, Fishbein MC. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003 Jan;22(1):58-69.</citation>
    <PMID>12531414</PMID>
  </reference>
  <reference>
    <citation>Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011 Nov;11(11):2405-13. doi: 10.1111/j.1600-6143.2011.03757.x. Epub 2011 Sep 22. Erratum in: Am J Transplant. 2013 Jan;13(1):241.</citation>
    <PMID>21942930</PMID>
  </reference>
  <reference>
    <citation>Nwakanma LU, Williams JA, Weiss ES, Russell SD, Baumgartner WA, Conte JV. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg. 2007 Nov;84(5):1556-62; discussion 1562-3.</citation>
    <PMID>17954062</PMID>
  </reference>
  <reference>
    <citation>Kobashigawa J, Crespo-Leiro MG, Ensminger SM, Reichenspurner H, Angelini A, Berry G, Burke M, Czer L, Hiemann N, Kfoury AG, Mancini D, Mohacsi P, Patel J, Pereira N, Platt JL, Reed EF, Reinsmoen N, Rodriguez ER, Rose ML, Russell SD, Starling R, Suciu-Foca N, Tallaj J, Taylor DO, Van Bakel A, West L, Zeevi A, Zuckermann A; Consensus Conference Participants. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2011 Mar;30(3):252-69. doi: 10.1016/j.healun.2010.11.003.</citation>
    <PMID>21300295</PMID>
  </reference>
  <reference>
    <citation>Berry GJ, Angelini A, Burke MM, Bruneval P, Fishbein MC, Hammond E, Miller D, Neil D, Revelo MP, Rodriguez ER, Stewart S, Tan CD, Winters GL, Kobashigawa J, Mehra MR. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant. 2011 Jun;30(6):601-11. doi: 10.1016/j.healun.2011.02.015.</citation>
    <PMID>21555100</PMID>
  </reference>
  <reference>
    <citation>Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, King KE, Kraus E, Lees LM, Melancon JK, Stewart ZA, Warren DS, Zachary AA, Montgomery RA. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant. 2009 Jan;9(1):231-5. doi: 10.1111/j.1600-6143.2008.02451.x. Epub 2008 Oct 31.</citation>
    <PMID>18976298</PMID>
  </reference>
  <reference>
    <citation>Wang H, Arp J, Liu W, Faas SJ, Jiang J, Gies DR, Ramcharran S, Garcia B, Zhong R, Rother RP. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. J Immunol. 2007 Oct 1;179(7):4451-63.</citation>
    <PMID>17878341</PMID>
  </reference>
  <reference>
    <citation>Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996 Dec;33(17-18):1389-401.</citation>
    <PMID>9171898</PMID>
  </reference>
  <reference>
    <citation>Rinder CS, Rinder HM, Smith BR, Fitch JC, Smith MJ, Tracey JB, Matis LA, Squinto SP, Rollins SA. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest. 1995 Sep;96(3):1564-72.</citation>
    <PMID>7657827</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 11, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2013</study_first_posted>
  <results_first_submitted>January 6, 2021</results_first_submitted>
  <results_first_submitted_qc>April 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 3, 2021</results_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Jignesh Patel, MD, PhD</investigator_full_name>
    <investigator_title>Medical Director of Heart Transplant Program, Cedars Sinai Heart Institute</investigator_title>
  </responsible_party>
  <keyword>cardiac transplantation</keyword>
  <keyword>immunosuppression</keyword>
  <keyword>acute cellular rejection</keyword>
  <keyword>antibody mediated rejection</keyword>
  <keyword>sensitization</keyword>
  <keyword>antibody production in cardiac patients</keyword>
  <keyword>panel reactive antibodies</keyword>
  <keyword>desensitization strategies in heart transplant patients</keyword>
  <keyword>complement activation</keyword>
  <keyword>complement c3d and c4d deposition</keyword>
  <keyword>terminal complement inhibition</keyword>
  <keyword>complement C5 binding</keyword>
  <keyword>Eculizumab</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>donor specific antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eculizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that supports the results of the study after deidentification and in accordance with Cedars Sinai data sharing agreements.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be available following publication and ending 3 years following article publication.</ipd_time_frame>
    <ipd_access_criteria>Data will be available to investigators whose proposed used of the data has been approved by Cedars Sinai IRB.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: Study Protocol including Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 9, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT02013037/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled following written informed consent for a protocol approved by the Institutional Review Board of Cedars-Sinai Medical Center (NCT02013037).The duration of the study included an open enrollment period and at least 12 months of post-transplant follow-up. All patients worked up for a heart transplant at the Heart Institute at Cedars-Sinai Medical Center (CSMC) with a panel reactive antibody (PRA) ≥ 70% at any time prior to screening.</recruitment_details>
      <pre_assignment_details>The trial enrolled a total of 36 sensitized participants age ≥ 18 years with a panel reactive antibody ≥70% at any time prior to study screening. Participants were included in the eculizumab treatment group if at least one donor specific antibody at MFI≥5000 was crossed but with negative prospective complement-dependent cytotoxicity crossmatch. 16 enrolled patients did not receive eculizumab.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Eculizumab</title>
          <description>Eculizumab: At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.&#xD;
On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.&#xD;
On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.&#xD;
On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.&#xD;
On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Awaiting Transplantation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transplanted without DSA</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The trial enrolled a total of 36 sensitized participants age ≥ 18 years with a panel reactive antibody (PRA) ≥70% at any time prior to study screening. Participants were included in the eculizumab treatment group if at least one DSA at MFI≥ 5000 was crossed but with negative prospective complement-dependent cytotoxicity (CDC) crossmatch. The eculizumab group consisted of 20 consecutive recipients transplanted between June 2, 2013 and July 31, 2018.</population>
      <group_list>
        <group group_id="B1">
          <title>Eculizumab</title>
          <description>Eculizumab: At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.&#xD;
On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.&#xD;
On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.&#xD;
On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.&#xD;
On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" lower_limit="44" upper_limit="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Non-Caucasian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non ischemic heart failure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time on waiting list</title>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129" lower_limit="46" upper_limit="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Long term mechanical circulatory support (MCS) or extra-corporeal membrane oxygena at transplant</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Combined transplantation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Retransplantation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior blood transfusion</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior pregnancy (women)</title>
          <population>The analysis population includes only the number of women (16)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-transplant diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-transplant hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum creatinine</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.35" lower_limit="1" upper_limit="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction</title>
        <description>The efficacy of Eculizumab will be assessed by a composite endpoint of:&#xD;
the incidence of pathologic AMR with a Grade ≥ 2&#xD;
the incidence of left ventricular dysfunction, as defined by a left ventricular ejection fraction (LVEF) ≤ 40% or a decrease of &gt;15% from baseline prior to the initiation of Eculizumab treatment.</description>
        <time_frame>up to 26 weeks post heart transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eculizumab</title>
            <description>Administration of Eculizumab to heart transplant recipients at Cedars Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, for the prevention of antibody-mediated rejection.&#xD;
Eculizumab: At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.&#xD;
On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.&#xD;
On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.&#xD;
On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.&#xD;
On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction</title>
          <description>The efficacy of Eculizumab will be assessed by a composite endpoint of:&#xD;
the incidence of pathologic AMR with a Grade ≥ 2&#xD;
the incidence of left ventricular dysfunction, as defined by a left ventricular ejection fraction (LVEF) ≤ 40% or a decrease of &gt;15% from baseline prior to the initiation of Eculizumab treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Survival at 12 Months Post Heart Transplantation</title>
        <description>The study will assess overall survival at 12 months following heart transplantation.</description>
        <time_frame>1 year post heart transplant</time_frame>
        <population>20 participants were included in the Eculizumab study</population>
        <group_list>
          <group group_id="O1">
            <title>Eculizumab</title>
            <description>Administration of Eculizumab to heart transplant recipients at Cedars Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, for the prevention of antibody-mediated rejection.&#xD;
Eculizumab: At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.&#xD;
On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.&#xD;
On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.&#xD;
On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.&#xD;
On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Survival at 12 Months Post Heart Transplantation</title>
          <description>The study will assess overall survival at 12 months following heart transplantation.</description>
          <population>20 participants were included in the Eculizumab study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hemodynamic Compromise at 6 Months Post Transplant</title>
        <description>The incidence of patient hemodynamic compromise will be assessed at 6 months post transplant, as defined by any one of the following:&#xD;
a 20% decrease in LVEF from baseline&#xD;
a LVEF &lt; 40%&#xD;
a 25% decrease in cardiac index from baseline&#xD;
a cardiac index &lt; 2.0&#xD;
the need for inotropic support</description>
        <time_frame>6 months post heart transplant</time_frame>
        <population>20 participants were included in the Eculizumab study</population>
        <group_list>
          <group group_id="O1">
            <title>Eculizumab</title>
            <description>Administration of Eculizumab to heart transplant recipients at Cedars Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, for the prevention of antibody-mediated rejection.&#xD;
Eculizumab: At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.&#xD;
On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.&#xD;
On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.&#xD;
On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.&#xD;
On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hemodynamic Compromise at 6 Months Post Transplant</title>
          <description>The incidence of patient hemodynamic compromise will be assessed at 6 months post transplant, as defined by any one of the following:&#xD;
a 20% decrease in LVEF from baseline&#xD;
a LVEF &lt; 40%&#xD;
a 25% decrease in cardiac index from baseline&#xD;
a cardiac index &lt; 2.0&#xD;
the need for inotropic support</description>
          <population>20 participants were included in the Eculizumab study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hemodynamic Compromise at 1 Year Post Transplant</title>
        <description>The incidence of patient hemodynamic compromise will be assessed at one year post transplant, as defined by any one of the following:&#xD;
a 20% decrease in LVEF from baseline&#xD;
a LVEF &lt; 40%&#xD;
a 25% decrease in cardiac index from baseline&#xD;
a cardiac index &lt; 2.0&#xD;
the need for inotropic support</description>
        <time_frame>1 year post heart transplant</time_frame>
        <population>20 participants participated in the eculizumab study</population>
        <group_list>
          <group group_id="O1">
            <title>Eculizumab</title>
            <description>Administration of Eculizumab to heart transplant recipients at Cedars Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, for the prevention of antibody-mediated rejection.&#xD;
Eculizumab: At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.&#xD;
On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.&#xD;
On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.&#xD;
On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.&#xD;
On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hemodynamic Compromise at 1 Year Post Transplant</title>
          <description>The incidence of patient hemodynamic compromise will be assessed at one year post transplant, as defined by any one of the following:&#xD;
a 20% decrease in LVEF from baseline&#xD;
a LVEF &lt; 40%&#xD;
a 25% decrease in cardiac index from baseline&#xD;
a cardiac index &lt; 2.0&#xD;
the need for inotropic support</description>
          <population>20 participants participated in the eculizumab study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Antibody Mediated Rejection (AMR)</title>
        <description>The study assessed the number of patients who develop AMR as well as the total number of episodes of AMR.</description>
        <time_frame>up to 1 year post heart transplant</time_frame>
        <population>20 participants were treated in the eculizumab study</population>
        <group_list>
          <group group_id="O1">
            <title>Eculizumab</title>
            <description>Administration of Eculizumab to heart transplant recipients at Cedars Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, for the prevention of antibody-mediated rejection.&#xD;
Eculizumab: At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.&#xD;
On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.&#xD;
On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.&#xD;
On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.&#xD;
On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Antibody Mediated Rejection (AMR)</title>
          <description>The study assessed the number of patients who develop AMR as well as the total number of episodes of AMR.</description>
          <population>20 participants were treated in the eculizumab study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With of Acute Cellular Rejection (ACR)</title>
        <description>The study assessed the number of participants with of Acute Cellular Rejection (ACR)</description>
        <time_frame>up to 1 year post heart transplant</time_frame>
        <population>20 participants were treated in the eculizumab study</population>
        <group_list>
          <group group_id="O1">
            <title>Eculizumab</title>
            <description>Administration of Eculizumab to heart transplant recipients at Cedars Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, for the prevention of antibody-mediated rejection.&#xD;
Eculizumab: At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.&#xD;
On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.&#xD;
On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.&#xD;
On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.&#xD;
On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With of Acute Cellular Rejection (ACR)</title>
          <description>The study assessed the number of participants with of Acute Cellular Rejection (ACR)</description>
          <population>20 participants were treated in the eculizumab study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Cardiac Allograft Vasculopathy (CAV) by Intravascular Ultrasound (IVUS)</title>
        <description>Development of cardiac allograft vasculopathy at 1 year determined by intravascular ultrasound defined as change in site-matched maximal intimal thickness ≥ 0.5mm from baseline to 1 year.</description>
        <time_frame>up to 1 year post heart transplant</time_frame>
        <population>20 enrolled patients were treated on the study</population>
        <group_list>
          <group group_id="O1">
            <title>Eculizumab</title>
            <description>Eculizumab: At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.&#xD;
On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.&#xD;
On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.&#xD;
On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.&#xD;
On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Cardiac Allograft Vasculopathy (CAV) by Intravascular Ultrasound (IVUS)</title>
          <description>Development of cardiac allograft vasculopathy at 1 year determined by intravascular ultrasound defined as change in site-matched maximal intimal thickness ≥ 0.5mm from baseline to 1 year.</description>
          <population>20 enrolled patients were treated on the study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Evolution of DSA: Donor Specific Antibody Post Transplantation</title>
        <description>Number of Participants who develop de novo donor specific antibody (DSA) in the first year following transplantation was determined.</description>
        <time_frame>Up to 1 year post transplant</time_frame>
        <population>20 enrolled patients were treated on the study</population>
        <group_list>
          <group group_id="O1">
            <title>Eculizumab</title>
            <description>Eculizumab: At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.&#xD;
On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.&#xD;
On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.&#xD;
On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.&#xD;
On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Evolution of DSA: Donor Specific Antibody Post Transplantation</title>
          <description>Number of Participants who develop de novo donor specific antibody (DSA) in the first year following transplantation was determined.</description>
          <population>20 enrolled patients were treated on the study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year post transplant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Eculizumab</title>
          <description>Administration of Eculizumab to heart transplant recipients at Cedars Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, for the prevention of antibody-mediated rejection.&#xD;
Eculizumab: At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.&#xD;
On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.&#xD;
On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.&#xD;
On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.&#xD;
On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit.&#xD;
2 deaths were reported in participants who received eculizumab. There were 6 deaths in participants who did not complete the study and did not receive eculizumab.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral infections</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Bacterial Infections</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fungal infections</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jignesh Patel</name_or_title>
      <organization>Cedars Sinai Smidt Heart Institute</organization>
      <phone>310-248-8300</phone>
      <email>jignesh.patel@cshs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

